SYNAPTOGENIX, INC.

Newark, NJ · Biotech · Public

Bryostatin-1, a protein kinase C epsilon activator molecule for Alzheimer's disease treatment

Grants
$4.5M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
23
2 granted · 21 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Long-term therapeutic effects of synthetic bryostatin-1 in advanced AD without memantine$2,719,310
Federal grantDepartment of Health and Human Services · Phase II · Long-term therapeutic effects of synthetic bryostatin-1 in advanced AD without memantine$1,732,392
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1529PGI HOLDING CORPORATION——
1530EUNOIA BIO TECH, LLC——
1531Juno Therapeutics, Inc.—$1.0B
1532SYNAPTOGENIX, INC.——
1533Akeso——
1534Ctrl Therapeutics——
1535Human Immunology Biosciences——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 23
  • Treatment Of Amyotrophic Lateral Sclerosis Using Pkc Activatorsapplication
  • Methods For Repairing Nerve Damage Using Pkc Activating Therapeutic Agentsapplication
  • Methods Of Treating And Preventing Neurodegenerative Diseases With Hgf Activating Compoundsapplication
  • Halogenated Esters Of Cyclopropanated Unsaturated Fatty Acids For Use In The Treatment Of Neurodegenerative Diseasesgranted
  • Treatment Of Multiple Sclerosis Using Pkc Activatorsapplication
  • Treatment Of Optic Nerve Inflammation Using Pkc Activatorsapplication
  • Pkc-activating Compounds For The Treatment Of Neurodegenerative Diseasesapplication
  • Pkc-activating Compounds For The Treatment Of Neurodegenerative Diseasesgranted
  • Method Of Inducing Synaptogenesis By Administering Angiotensin And Analogues Thereofapplication
  • Treatment Of Amyotrophic Lateral Sclerosis Using Pkc Activatorsapplication
  • Methods Of Treating And Preventing Neurodegenerative Diseases With Hgf Activating Compoundsapplication
  • Methods And Compositions For Treatment Of Alzheimer's Disease And Other Neurodegenerative Disordersapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.